Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff

Merck secured FDA approval for a subcutaneous version of its blockbuster cancer drug Keytruda, offering patients a significantly more convenient 1-2 minute injection compared to the traditional 30-minute IV infusion. This innovation, expected to see 30-40% patient adoption within 18-24 months, is strategically important for Merck, potentially mitigating future revenue erosion from biosimilar competition for its nearly $30 billion annual revenue driver. Despite this positive development, Merck's stock closed down 1.4%, underperforming the broader Medical-Ethical Drugs industry group and trading below key moving averages, reflecting broader investor sentiment or focus on its year-to-date decline.

Analysis

Merck has secured FDA approval for a subcutaneous formulation of its leading oncology drug, Keytruda, a strategic move aimed at defending its franchise revenue ahead of anticipated biosimilar competition post-2028. Keytruda, which generated nearly $29.5 billion in 2023 sales, is a critical component of Merck's portfolio, with peak sales forecast at $33.7 billion in 2028. The new formulation significantly enhances patient convenience by reducing administration time to one-to-two minutes from the standard 30-minute infusion and eliminating the need for an implanted port. Management projects a 30% to 40% patient conversion rate within 18 to 24 months, primarily among those on monotherapy or with early-stage cancers. However, the market's reaction was negative; Merck's stock (MRK) closed down 1.4% and continues to trade below its 50-day and 200-day moving averages, reflecting an 18% year-to-date decline. This disconnect suggests the approval was either already priced in or overshadowed by broader concerns about the stock's performance and the long-term competitive landscape, which this innovation only partially mitigates.

Key Decisions for Investors

• Long-term investors should view the subcutaneous Keytruda approval as a positive life-cycle management strategy that partially de-risks the significant revenue cliff from biosimilar entry after 2028.
• Given the negative price action and weak technicals, with the stock trading below key moving averages and underperforming its industry group, investors should be cautious about expecting an immediate positive re-rating from this news alone.
• It is prudent to monitor upcoming catalysts that will clarify the new formulation's commercial potential, specifically the yet-to-be-announced pricing and the results of the patient preference study expected next month, which are crucial for validating the 30-40% adoption forecast.